Digoxin measurements in general practice.

Holt, D W; Williamson, JD

doi:10.1111/j.1365-2125.1977.tb00720.x

Cited by 6 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As suggested in previous studies, SDC varied widely among patients (1,6,11,12). Part of this variation is explained by differences in systemic availability among the four digitalis preparations.…”

Section: Discussionmentioning

confidence: 77%

“…The findings probably reflect the inherent problems discussed above as well as the likelihood that SDC does not in variably correlate with concentrations at sites of pharmacological activity (11). Thus, glyco side concentrations in serum should be but one of the factors considered by clinicians who evaluate potentially drug-related subjective symptoms reported by patients receiving digi talis preparations (6).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Digoxin Concentrations and Subjective Manifestations of Toxicity

Ochs¹,

Greenblatt²,

Harmatz³

et al. 1980

Pharmacology

View full text Add to dashboard Cite

The relation of serum digoxin concentrations (SDC) to subjective manifestations of toxicity was evaluated in 300 patients with permanent transvenous pacemakers. All had been receiving the same daily dose of a glycoside preparation for at least 6 months prior to the study. The most commonly prescribed preparations were β -acetyldigoxin (n = 186) and β-methyldigoxin (n = 70); a smaller number of patients received digoxin (n = 34) and lanatoside-C (n = 10). Subjective symptoms of gastrointestinal, neuromuscular, and psychiatric toxicity were evaluated by questionnaire concurrent with measurement of SDC. Daily glycoside dose correlated poorly with steady-state SDC. Age, sex, dose, body surface area, and serum creatinine concentration explained only a small fraction of overall variability in SDC. Subjective symptom scores tended to increase at higher SDC, but the trends did not approach significance. The independent variables collectively explained no more than 6% of the variability in toxicity scores. Thus, the occurrence of extracardiac symptoms of digitalis toxicity is only weakly related to serum glycoside concentration, probably because such symptoms are very nonspecific and can occur in patients with cardiac disease regardless of digitalis therapy.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Serum Digoxin Concentrations and Subjective Manifestations of Toxicity

Ochs¹,

Greenblatt²,

Harmatz³

et al. 1980

Pharmacology

View full text Add to dashboard Cite

show abstract

Digoxin-Prescribing

Weintraub¹

1979

JAMA

View full text Add to dashboard Cite

We examined digoxin-prescribing in 47,000 prescriptions written predominantly by physicians in a large family medicine practice. Two hundred fifty-four patients received 511 digoxin prescriptions. Dose adjustments for age (16% decrease in patients older than 64 years), for renal disease (33% decrease), and for atrial fibrillation (39% increase) followed good prescribing practices. Appropriately lower loading doses were used for digitalization. However, despite continuing concern over the bioavailability of generic digoxin tablets, less than 40% of digoxin prescriptions in this study were written for the innovator's brand-name product (Lanoxin).

show abstract

The Logistics of Drug Monitoring

Goulding

1980

Ciba Foundation Symposium 74 ‐ Drug Concentrations in Neuropsychiatry

View full text Add to dashboard Cite

Digoxin measurements in general practice.

Cited by 6 publications

References 21 publications

Serum Digoxin Concentrations and Subjective Manifestations of Toxicity

Serum Digoxin Concentrations and Subjective Manifestations of Toxicity

Digoxin-Prescribing

The Logistics of Drug Monitoring

Contact Info

Product

Resources

About